Analysis of the impact of the MDD (Medical Device Directive) review amendments on active implants
This article was originally published in Clinica
The changes proposed by the European Commission and the European Parliament to the Active Implantable Medical Device Directive (AIMDD) relating to active implantable medical devices (90/385) are more fundamental than the current proposals to revise the Medical Devices Directive (MDD - 93/42). So says vice-president of Quintiles Consulting Mika Reinikainen, who reports on the main amendments to the AIMDD proposed at the Parliament's March 29 session
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.